December 18, 2025 8:00am

Economic jitters as weak trends endeavor a tremendous amount of uncertainty

Updating: Headline annual inflation rate was 2.7%. The 12-month rate for core CPI, which excludes food and energy, was 2.6%. 

It's a good clue (the highs) to be reducing “some” exposures, exiting some also-rans or questionable data and clinical delays

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t! 

 

The peril facing the cell and gene therapy (C&GT) sector’s share pricing isn’t just applications of macro or even micro econs, sentiment or algorithms within electronic trading; it’s losing highly reliable, accurate and transparent data.

 

RMi Closing Bell: Rattled … https://www.regmedinvestors.com/articles/14234

RMi Research Note: Capricor Therapeutics (CAPR) overvalued, overbought and headed to a BIGGER slide … https://www.regmedinvestors.com/articles/14233

 

Updated ... Thursday: The pre-open Dow futures are UP +0.41% or (+199 points), the S&P futures are UP +0.68% or (+47 points) and the Nasdaq futures are UP +1.28% or (+319 points)

  • Stock futures are rising with the prediction inflation grew at a 3.1% pace on a year-over-year basis Thursday, 12/18
  • European markets made gains,
  • Asia Pacific markets fell.

 

Economic data reporting:Updating: Headline annual inflation rate was 2.7%. The 12-month rate for core CPI, which excludes food and energy, was 2.6%.

  • Economists HAD predict that headline inflation grew at a 3.1% pace on a year-over-year basis; excluding food and energy, core CPI is forecast to post an annual rate of 3.0%.

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Wednesday: The Dow closed DOWN -228.29 points or -0.47%, the S&P closed DOWN -78.75 points or -1.16% while the Nasdaq closed DOWN -418.139 points or -1.81%
  • Tuesday: The Dow closed DOWN -302.30 points or -0.62%, the S&P closed DOWN -16.25 points or -0.24 % while the Nasdaq closed UP +54.049 points or +0.23%
  • Monday: The Dow closed DOWN -41.31 points or -0.09%, the S&P closed DOWN -10.90 points or -0.16 % while the Nasdaq closed DOWN -137.757 points or -0.59%
  • Last week: The S&P 500 is down -0.6%, the Dow is up +1% and the Nasdaq is -1.6%.
  • The previous week: The S&P 500 is up +0.3%, the Dow +0.5% and the Nasdaq is up +0.9%.
  • November ended: the S&P 500 and Dow were slightly higher, as the Nasdaq fell 2%,

 

Q4 – December, 4 positive and 9 negative closes

  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • I am resisting and restricting my comments, feeling it but not seeing the upside!

 

 

The BOTTOM LINE: Artificial-intelligence stocks knocked share pricing into a gulley.

Maybe, just maybe … we could be eyeing a sector share pricing ...recovery from the sell-off as investors wait for the consumer inflation (CPI) data that could help set expectations for multiple paths of economic consequences and share pricing?

  • Too, too many declining sessions could mean some upside buying is warranted 

Welcome to my world of defining the “grey’ in our universe!

  • With a downside end-of-month and year rotation and rebalance, In the last of December and 2025, it means investors have to be careful of slippage targets.

 

3rd week of December:

  • 12/17 – Wednesday closed negative with 12 positive, 26 negative and 2 flats
  • 12/16- Tuesday closed negative with 17 positive, 21 negative and 2 flats
  • 12/15 – Monday closed negative with 15 positive, 23 negative and 2 flats

2nd week:

  • 12/12 – Friday closed negative with 12 positive, 26 negative and 2 flats
  • 12/11 – Thursday closed negative with 18 positive, 19 negative and 3 flats
  • 12/10 – Wednesday closed positive with 24 positive, 12 negative and 4 flats
  • 12/9 - Tuesday closed negative with 10 positive, 27 negative and 3 flats
  • 12/8 - Monday closed positive with 22 positive, 16 negative and 2 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.